Private company

Baudax Bio, Inc.

Last updated Oct 16, 2026.

Overview

  • IndustryPharmaceutical Preparations
  • HeadquartersPA
  • Incorporated inPA2
  • Business address490 Lapp Road, Malvern, Pa 193552
  • Filer category, Emerging growth company2

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-4477.0%Operating margin3
-4633.2%Net margin3
17.5%Revenue growth, 20223
-$27.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue20¢$7.0M
  • Research and development11¢$3.9M
  • Selling, general and admin69¢$24.1M

Out of $1.3M in revenue.3 The company lost money this year.

Financial statements

Revenue43$1.3M in 2022+157% since 2020
0$500.0K$1.0M$1.5M2020: $493.0K$493.0K20202021: $1.1M$1.1M2021+119%2022: $1.3M$1.3M2022+18%
Operating income5643-$56.8M in 2022−23% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$73.5M-$73.5M20182019: -$32.5M-$32.5M2019−56%2020: -$74.8M-$74.8M2020+130%2021: -$19.0M-$19.0M2021−75%2022: -$56.8M-$56.8M2022+199%
Net income5643-$58.8M in 2022−20% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$73.7M-$73.7M20182019: -$32.6M-$32.6M2019−56%2020: -$76.1M-$76.1M2020+134%2021: -$19.8M-$19.8M2021−74%2022: -$58.8M-$58.8M2022+197%
Fiscal year201720182019202020212022
Revenue$493.0K4$1.1M3$1.3M3
Cost of revenue$1.7M4$2.4M3$7.0M3
Research and development$35.6M5$20.1M6$9.1M4$3.1M3$3.9M3
Selling, general and admin$27.0M6$43.3M4$45.3M3$24.1M3
Operating income-$73.5M5-$32.5M6-$74.8M4-$19.0M3-$56.8M3
Interest$1.4M4$2.3M4
Income tax$05$06$04$03$03
Net income-$73.7M5-$32.6M6-$76.1M4-$19.8M3-$58.8M3
Earnings per share-$361.163-$177.303
Earnings per share (diluted)-$361.163-$177.303

Compare Baudax Bio, Inc. with another company

Former names

  • Recro Enterprises, Inc.Jun 24, 2019 to Jun 24, 20192

Recent filings

  1. Feb 28, 20248-K
  2. Dec 13, 20238-K
  3. Nov 20, 202310-Q
  4. Nov 15, 20238-K
  5. Oct 25, 20238-K
  6. Oct 13, 20238-K
  7. Oct 11, 20233 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
  8. Oct 6, 20238-K
  9. Sep 29, 20238-K
  10. Sep 21, 2023S-1/A
  11. Sep 7, 20238-K/A
  12. Sep 7, 2023DEF 14A
  13. Sep 5, 20238-K
  14. Sep 5, 2023S-1
  15. Aug 25, 20238-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1